Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
90 Leser
Artikel bewerten:
(0)

Lifshitz & Miller Law Firm Announces Investigation of Coty, Inc., Galena Biopharma, Inc., InnerWorkings, Inc., IPC The Hospitalist Company, Inc. and K12, Inc.

NEW YORK, Feb. 26, 2014 /PRNewswire/ --

Coty, Inc.

Lifshitz & Millerannounces that a class action was filed in the United States District Court for the Northern District of California, alleging Coty, Inc. ("COTY") issued false and misleading statements in connection with the Initial Public Offering ("IPO") by failing to disclose its sales were deteriorating and demand for its products from retailers were declining.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Galena Biopharma, Inc.

Lifshitz & Millerannounces that it is investigating potential claims against the officers and board of Galena Biopharma, Inc. ("Galena") (GALE). On February 12, 2014, TheStreet reported that there is evidence linking Galena to a stock-promotions firm encouraging improper stock promotion. Galena insiders have made millions of dollars by selling company stock.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

InnerWorkings, Inc.

Lifshitz & Millerannounces that it is investigating potential claims against the officers and board of InnerWorkings, Inc. ("InnerWorkings") (INWK). On February 18, 2014, InnerWorkings reported that it believes the former owner of Productions Graphics artificially inflated results to meet earn-out targets and induce InnerWorkings to make earn-out payments relating to the Productions Graphics acquisition. As a result, InnerWorkings will restate its prior financial statements in its upcoming 10-K filing.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

IPC The Hospitalist Company, Inc.

Lifshitz & Millerannounces that it is investigating potential claims against the officers and board of IPC The Hospitalist Company, Inc. (IPCM). On December 9, 2013, the U.S. Department of Justice announced that it has intervened in a lawsuit charging IPCM with fraud in connection with as much as $125 million in revenues obtained from Medicare and Medicaid in violation of the False Claims Act.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

K12, Inc.

Lifshitz & Millerannounces that a class action was filed in the United States District Court for the Eastern District of Virginia, alleging that K12, Inc. (LRN) issued false and misleading statements during the period from March 11, 2013 through October 9, 2013 by failing to disclose that the Company had not adequately invested in promotional efforts to enroll new students in fiscal 2014, and that the Company's enrollment centers did not have adequate school-by-school planning tools for incoming student applications.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Lifshitz & Miller is a New York based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.jlclasslaw.com.

ATTORNEY ADVERTISING. © 2014 Lifshitz & Miller. The law firm responsible for this advertisement is Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz & Miller
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@jlclasslaw.com

SOURCE Lifshitz & Miller Law Firm

© 2014 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.